T. Kojima

发表

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs.

K. Sasahara, T. Nitanai, T. Habara, 1981, Journal of pharmaceutical sciences.

Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.

M. Hashida, N. Tanigawa, S. Muranishi, 1981, Gan.

High-performance liquid chromatographic method for determination of cefmetazole in human serum

K. Sasahara, M. Sekine, T. Kojima, 1982, Antimicrobial Agents and Chemotherapy.

Improvement of bioavailability of poorly intestinally absorbed drugs from medium-chain glyceride base. Enhancement of the rectal absorption of cefmetazole sodium in rabbits.

R. Okada, K. Sasahara, M. Sekine, 1984, Chemical and pharmaceutical bulletin.

Studies of diabetic nephropathy. I. Effects of storage time and temperature on microalbuminuria.

K. Nakazato, K. Shiba, F. Hara, 1994, Biological & pharmaceutical bulletin.

Improvement of bioavailability of poorly absorbed drugs. I. Effect of medium chain glyceride base on the rectal absorption of cefmetazole sodium in rats.

S. Awazu, R. Okada, K. Sasahara, 1984, Journal of Pharmacobio-Dynamics.

Mitomycin C‐dextran conjugate: a novel high molecular weight pro‐drug of mitomycin C

M. Hashida, S. Muranishi, H. Sezaki, 1980, The Journal of pharmacy and pharmacology.

Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.

M. Hashida, S. Muranishi, H. Sezaki, 1978, Gan.

Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate.

M. Hashida, S. Muranishi, H. Sezaki, 1978, Chemical & pharmaceutical bulletin.

Timed-Release of Mitomycin C from Its Agarose Bead Conjugate

M. Hashida, Yoshiteru Takahashi, S. Muranishi, 1977 .